CJC-1295 research guide for Sarmego. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Sarmego looking to source CJC-1295, the first thing to know is that this compound is available only through an online research supply market. The upside of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers more rigorous quality data than local retail ever could. Separating properly characterised CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram showing ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to evaluate CJC-1295 vendors rigorously — the framework here apply whether you are in Sarmego or anywhere else.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Sarmego comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
The first step for any Sarmego researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — organic rankings are no guide to actual CJC-1295 quality. Mass spectrometry in the COA establishes that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. For Sarmego researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before placing larger orders is standard practice in the community. The lyophilised (freeze-dried) form of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Sarmego
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means safety data comes from animal studies, in-vitro work, and limited human observations — rather than the comprehensive clinical trial data that characterises approved medications. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. The primary quality-related safety risk in CJC-1295 research is endotoxin contamination from poor sourcing — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not approved for human use and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
